Mineralys to present lorundrostat Phase 3 data at ASN Kidney Week 2026
Mineralys Therapeutics announced presentation of new Launch-HTN trial data for lorundrostat at ASN Kidney Week 2026 (Oct 21–25, Denver). The aldosterone antagonist targets hypertension and kidney disease comorbidities.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
Mineralys (MLYS) disclosed that Phase 3 Launch-HTN trial results for lorundrostat will be presented at the American Society of Nephrology's annual conference in Denver, October 21–25, 2026. No efficacy, safety or regulatory outcomes were disclosed in the announcement.
Why it matters
Lorundrostat is a non-steroidal aldosterone synthase inhibitor in development for hypertension and aldosterone-driven kidney disease. Presentation of Phase 3 data at a major nephrology conference signals progression toward potential regulatory submission and commercialization. Positive or negative trial outcomes could materially affect clinical development trajectory, investor confidence and valuation.
Market transmission
Favorable efficacy/safety data would strengthen regulatory pathway and reduce clinical risk, potentially supporting equity valuation and partnership/licensing discussions. Adverse or neutral results would increase development risk and delay commercialization timelines. Kidney disease and hypertension represent large addressable markets; competitive positioning versus existing aldosterone antagonists (spironolactone, eplerenone) and newer agents will depend on efficacy, tolerability and renal outcomes.
What to watch
Actual trial results (efficacy endpoints, safety profile, renal outcomes, patient populations); regulatory feedback or guidance post-presentation; competitive landscape updates; partnership or financing announcements; stock reaction on data release.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.